Matches in SemOpenAlex for { <https://semopenalex.org/work/W2324975026> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W2324975026 abstract "Background KRAS gene mutations are associated with a worse metastatic colorectal cancer (mCRC) prognosis. Purpose To assess the effectiveness of the first-line treatment of mCRC according to KRAS mutational status. Materials and methods Retrospective and observational study. It included patients who started chemotherapy for mCRC between October 2011 and June 2012. Effectiveness measure was the median progression-free survival (PFS) and response rate measured by RECIST criteria. Results 79 patients. Mean age at diagnosis: 66 years old, 54% men. Median PFS was 11 months. The KRAS mutational status was determined for 88.6% of the patients, of which 52.9% was mutated. Median PFS was 13 and 10 months in wild-type and mutated KRAS patients respectively. Although statistically significant differences were not found for a 95% confidence interval (CI) (p = 0.058), they were considered a trend. A response was detected in 50% and 54.5% of wild-type and mutated KRAS patients respectively. In the mutated KRAS group, median PFS was 9 and 10 months in bevacizumab and other regimes without targeted treatment respectively (p = 0.740). 51.9% and 20% of patients treated with bevacizumab and other regimes without targeted treatment respectively responded. In the wild-type KRAS group, median PFS was 14 and 10 months in cetuximab/panitumumab and bevacizumab treated patients respectively (p = 0.136). 50% and 54.5% of patients treated with cetuximab/panitumumab and bevacizumab respectively responded. In both groups, treatment was mostly associated with oxaliplatin and 5-fluorouracil or capecitabine. Conclusions There was a trend to higher median PFS in wild-type KRAS patients, fitting with the worse prognosis in mutated KRAS patients. Response rate and median PFS were similar in wild-type and mutated KRAS patients regardless of the targeted therapy used. No conflict of interest." @default.
- W2324975026 created "2016-06-24" @default.
- W2324975026 creator A5001652409 @default.
- W2324975026 creator A5015459860 @default.
- W2324975026 creator A5018641877 @default.
- W2324975026 creator A5020014361 @default.
- W2324975026 creator A5027343561 @default.
- W2324975026 creator A5036694752 @default.
- W2324975026 date "2014-02-24" @default.
- W2324975026 modified "2023-09-27" @default.
- W2324975026 title "CP-053 Effectiveness assessment of first-line treatment in metastatic colorectal cancer according to mutational KRAS status" @default.
- W2324975026 doi "https://doi.org/10.1136/ejhpharm-2013-000436.52" @default.
- W2324975026 hasPublicationYear "2014" @default.
- W2324975026 type Work @default.
- W2324975026 sameAs 2324975026 @default.
- W2324975026 citedByCount "0" @default.
- W2324975026 crossrefType "journal-article" @default.
- W2324975026 hasAuthorship W2324975026A5001652409 @default.
- W2324975026 hasAuthorship W2324975026A5015459860 @default.
- W2324975026 hasAuthorship W2324975026A5018641877 @default.
- W2324975026 hasAuthorship W2324975026A5020014361 @default.
- W2324975026 hasAuthorship W2324975026A5027343561 @default.
- W2324975026 hasAuthorship W2324975026A5036694752 @default.
- W2324975026 hasConcept C121608353 @default.
- W2324975026 hasConcept C126322002 @default.
- W2324975026 hasConcept C143998085 @default.
- W2324975026 hasConcept C167135981 @default.
- W2324975026 hasConcept C2776694085 @default.
- W2324975026 hasConcept C2776907518 @default.
- W2324975026 hasConcept C2777802072 @default.
- W2324975026 hasConcept C2777909004 @default.
- W2324975026 hasConcept C2778332735 @default.
- W2324975026 hasConcept C2779998722 @default.
- W2324975026 hasConcept C2780739268 @default.
- W2324975026 hasConcept C2780962732 @default.
- W2324975026 hasConcept C2781187634 @default.
- W2324975026 hasConcept C526805850 @default.
- W2324975026 hasConcept C71924100 @default.
- W2324975026 hasConcept C90924648 @default.
- W2324975026 hasConceptScore W2324975026C121608353 @default.
- W2324975026 hasConceptScore W2324975026C126322002 @default.
- W2324975026 hasConceptScore W2324975026C143998085 @default.
- W2324975026 hasConceptScore W2324975026C167135981 @default.
- W2324975026 hasConceptScore W2324975026C2776694085 @default.
- W2324975026 hasConceptScore W2324975026C2776907518 @default.
- W2324975026 hasConceptScore W2324975026C2777802072 @default.
- W2324975026 hasConceptScore W2324975026C2777909004 @default.
- W2324975026 hasConceptScore W2324975026C2778332735 @default.
- W2324975026 hasConceptScore W2324975026C2779998722 @default.
- W2324975026 hasConceptScore W2324975026C2780739268 @default.
- W2324975026 hasConceptScore W2324975026C2780962732 @default.
- W2324975026 hasConceptScore W2324975026C2781187634 @default.
- W2324975026 hasConceptScore W2324975026C526805850 @default.
- W2324975026 hasConceptScore W2324975026C71924100 @default.
- W2324975026 hasConceptScore W2324975026C90924648 @default.
- W2324975026 hasLocation W23249750261 @default.
- W2324975026 hasOpenAccess W2324975026 @default.
- W2324975026 hasPrimaryLocation W23249750261 @default.
- W2324975026 isParatext "false" @default.
- W2324975026 isRetracted "false" @default.
- W2324975026 magId "2324975026" @default.
- W2324975026 workType "article" @default.